Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative BP Management and Dexamethasone in NSCLC Surgery
NCT04209218Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexamethasone in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Peking University First Hospital. Primary endpoints: Overall Survival at 5 years and Incidence of organ injury and complications at 5 days. Started Apr 2020; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04209218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209218.